SAB Biotherapeutics, Inc. (SABS)
Upgrades & Downgrades
Latest SABS news
SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets
3 March 2022
Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.
SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study
26 January 2022
Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.
On Positive Virology Data, SAB Biotherapeutics' COVID-19 Drug To Move To Phase 3 In NIH ACTIV-2 Tria...
24 January 2022
SAB Biotherapeutics Inc (NASDAQ: SABS) has reported positive Phase 2 safety and efficacy data demonstrating that SAB-185 met the criteria required to move to Phase 3 in the National Institutes of Heal...
FDA Lab Testing Confirms SAB Biotherapeutics' COVID-19 Antibody Neutralizes Omicron Variant
16 December 2021
SAB Biotherapeutics Inc (NASDAQ: SABS) announced that SAB-185, its COVID-19 therapeutic candidate, retains neutralization activity against the omicron variant in an in vitro pseudovirus model. The re...
SAB Biotherapeutics' Influenza Candidate Achieves Primary Goal In Mid-Stage Study
1 December 2021
SAB Biotherapeutics Inc (NASDAQ: SABS) has announced data from a Phase 2a challenge study of SAB-176, its investigational therapy for treating seasonal influenza. SAB-176 is a quadrivalent fully human...